MXPA02012611A - Composicion anestesica, acuosa, clara. - Google Patents

Composicion anestesica, acuosa, clara.

Info

Publication number
MXPA02012611A
MXPA02012611A MXPA02012611A MXPA02012611A MXPA02012611A MX PA02012611 A MXPA02012611 A MX PA02012611A MX PA02012611 A MXPA02012611 A MX PA02012611A MX PA02012611 A MXPA02012611 A MX PA02012611A MX PA02012611 A MXPA02012611 A MX PA02012611A
Authority
MX
Mexico
Prior art keywords
clear aqueous
propofol
compositions
composition
bgr
Prior art date
Application number
MXPA02012611A
Other languages
English (en)
Spanish (es)
Inventor
Shilpa Kocharekar
Original Assignee
Bharat Serums Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums Vaccines Ltd filed Critical Bharat Serums Vaccines Ltd
Publication of MXPA02012611A publication Critical patent/MXPA02012611A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA02012611A 2000-06-21 2000-12-14 Composicion anestesica, acuosa, clara. MXPA02012611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN573MU2000 IN187686B (enExample) 2000-06-21 2000-06-21
PCT/IN2000/000124 WO2001097796A1 (en) 2000-06-21 2000-12-14 Clear aqueous anaesthetic composition

Publications (1)

Publication Number Publication Date
MXPA02012611A true MXPA02012611A (es) 2004-07-30

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012611A MXPA02012611A (es) 2000-06-21 2000-12-14 Composicion anestesica, acuosa, clara.

Country Status (26)

Country Link
US (1) US7138387B2 (enExample)
EP (1) EP1299095B1 (enExample)
JP (1) JP4907833B2 (enExample)
KR (1) KR100810066B1 (enExample)
CN (1) CN1254237C (enExample)
AP (1) AP2002002674A0 (enExample)
AT (1) ATE267592T1 (enExample)
AU (2) AU3597201A (enExample)
BG (1) BG107463A (enExample)
BR (1) BR0017268A (enExample)
CA (1) CA2414064C (enExample)
DE (1) DE60011149T2 (enExample)
DK (1) DK1299095T3 (enExample)
EA (1) EA005589B1 (enExample)
ES (1) ES2222271T3 (enExample)
HU (1) HUP0301646A3 (enExample)
IL (1) IL153387A0 (enExample)
IN (1) IN187686B (enExample)
MX (1) MXPA02012611A (enExample)
NO (1) NO20025999D0 (enExample)
NZ (1) NZ523643A (enExample)
PL (1) PL359624A1 (enExample)
PT (1) PT1299095E (enExample)
WO (1) WO2001097796A1 (enExample)
YU (1) YU2703A (enExample)
ZA (1) ZA200300336B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (enExample) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
DE60232271D1 (de) * 2001-12-28 2009-06-18 Eisai Corp North America Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
US20050239746A1 (en) * 2002-02-01 2005-10-27 Penkler Lawrence J Pharmaceutical composition
PL375874A1 (pl) 2002-07-29 2005-12-12 Transform Pharmaceuticals, Inc. Wodne kompozycje farmaceutyczne 2,6-diizopropylofenolu
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
LT1585548T (lt) * 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
CN1909893A (zh) * 2004-01-14 2007-02-07 株式会社大塚制药工场 含有丙泊酚的脂肪乳剂
WO2006030450A2 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
AU2006310044A1 (en) * 2005-08-12 2007-05-10 Bharat Serums & Vaccines Ltd. Aqueous anaesthetic compositions comprising propofol
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
US8563221B2 (en) * 2008-03-11 2013-10-22 3M Innovative Properties Company Phototools having a protective layer
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
WO2011011167A2 (en) 2009-07-21 2011-01-27 3M Innovative Properties Company Curable composition, method of coating a phototool, and coated phototool
KR101768237B1 (ko) 2009-09-16 2017-08-14 쓰리엠 이노베이티브 프로퍼티즈 컴파니 플루오르화된 코팅 및 그로 제조된 포토툴
WO2011034847A1 (en) 2009-09-16 2011-03-24 3M Innovative Properties Company Fluorinated coating and phototools made therewith
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) * 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
EP2484350B1 (de) * 2011-02-04 2016-04-20 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung, enthaltend einen Komplex eines Propofolsalzes mit einem Cyclodextrin
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
HRP20200567T1 (hr) * 2011-11-29 2020-06-26 Jurox Pty Ltd Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon
CN103263404B (zh) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 一种复合麻醉药物
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP3407875A4 (en) * 2016-01-29 2019-09-04 Cuda Anesthetics, LLC AQUEOUS PHARMACEUTICAL FORMULATION WITH PROPOFOL
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
NO20025999L (no) 2002-12-13
US20040014718A1 (en) 2004-01-22
YU2703A (sh) 2006-03-03
KR20030023875A (ko) 2003-03-20
WO2001097796A1 (en) 2001-12-27
ES2222271T3 (es) 2005-02-01
ZA200300336B (en) 2004-04-08
KR100810066B1 (ko) 2008-03-05
CN1454085A (zh) 2003-11-05
CN1254237C (zh) 2006-05-03
DE60011149D1 (de) 2004-07-01
PT1299095E (pt) 2004-10-29
AU2001235972B2 (en) 2005-07-21
CA2414064C (en) 2013-01-08
EP1299095A1 (en) 2003-04-09
JP4907833B2 (ja) 2012-04-04
HUP0301646A2 (hu) 2003-09-29
IN187686B (enExample) 2002-06-08
PL359624A1 (en) 2004-08-23
AP2002002674A0 (en) 2002-12-31
HUP0301646A3 (en) 2005-06-28
DK1299095T3 (da) 2004-10-11
AU3597201A (en) 2002-01-02
IL153387A0 (en) 2003-07-06
CA2414064A1 (en) 2001-12-27
NZ523643A (en) 2004-05-28
ATE267592T1 (de) 2004-06-15
JP2003535893A (ja) 2003-12-02
BR0017268A (pt) 2003-05-27
BG107463A (en) 2003-11-28
US7138387B2 (en) 2006-11-21
EP1299095B1 (en) 2004-05-26
DE60011149T2 (de) 2005-07-07
EA200300047A1 (ru) 2003-06-26
EA005589B1 (ru) 2005-04-28
NO20025999D0 (no) 2002-12-13

Similar Documents

Publication Publication Date Title
MXPA02012611A (es) Composicion anestesica, acuosa, clara.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
SE0001899D0 (sv) New compounds
DK1157037T3 (da) GCSF-konjugater
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
PL370111A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AR035735A1 (es) Composicion farmaceutica que se puede administrar por via oral, y el uso de la misma en la fabricacion de un medicamento
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
SI1819227T1 (sl) Farmacevtska formulacija decitabina
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
MX228228B (es) Composiciones de propofol claras, estables.
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
BR0109617A (pt) Composição farmacêutica, oligossacarìdeo, processo de preparação de oligossacarìdeos, e, utilização de oligossacarìdeos
HUP0303379A2 (hu) Savérzékeny vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
AR046464A1 (es) Multiparticulas de liberacion controlada con mejoradores de la disolucion
SE0002354D0 (sv) New formulation
AR038017A1 (es) Composicion anestesica acuosa y clara
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1

Legal Events

Date Code Title Description
FG Grant or registration